The work, led by Shearer, Antonson, Van Steenwinckel and colleagues, focuses on a problem that has complicated neonatal neuroscience for decades. Perinatal brain injury—including damage associated with oxygen deprivation, inflammation, infection or disrupted blood flow—cannot be studied in humans with the same experimental precision available in animals. Mice are widely used because they are practical and genetically tractable, while larger animals can more closely resemble human brain development in certain respects. Yet similarities in anatomy do not automatically mean that immune cells are at the same developmental stage.

Microglia are central to this challenge. Often described as the brain’s immune sentinels, they constantly survey neural tissue, remove damaged material and help shape connections between neurons. During early development, however, microglia are not simply defensive cells waiting for injury. They participate in the formation and refinement of neural circuits, regulate inflammatory signals, influence the survival of immature cells and help coordinate the transition from a developing to a mature nervous system. Their behavior therefore depends strongly on age and developmental context.

The new reference aims to make that context visible. Rather than treating “newborn,” “infant” or “juvenile” as interchangeable labels across species, the study examines microglial maturation as a biological process that can be compared across human and mouse development and then used to interpret large-animal models. This distinction is crucial because the same chronological age can represent very different stages of brain maturation in different species. A mouse that is described as neonatal may not possess microglia operating in a state equivalent to those in a human newborn.

At the cellular level, maturation can involve changes in morphology, gene activity, surface markers, metabolism and responses to environmental signals. Immature microglia may display molecular programs associated with construction and growth, while later stages are increasingly linked to surveillance, maintenance and coordinated responses to damage. After an injury, these programs can shift again. Cells may become activated, alter their shape, change their gene expression and release signaling molecules that affect neurons, blood vessels and other glial cells. Interpreting such changes requires knowing whether they reflect injury—or simply normal development.

That issue has direct consequences for translational research. An experimental treatment may appear to reduce inflammation in a mouse model while acting on a developmental pathway that is not dominant in human infants. Conversely, a response that looks excessive in an animal may represent a normal stage of immune maturation rather than pathological activation. By placing microglial states on a cross-species developmental map, the researchers seek to reduce these mismatches and help investigators select models whose biology is aligned with the human condition being studied.

Large-animal models are particularly important because their brains, body sizes, gestational patterns and postnatal development can provide intermediate or complementary perspectives between rodents and people. They are also more suitable for some forms of imaging, monitoring and clinically relevant intervention. But their value depends on careful biological benchmarking. The study’s framework is designed to help researchers ask a more precise question than whether an animal is simply “similar” to a human: which aspects of microglial maturation are shared, which are different and at what developmental point do those differences matter most?

The implications extend beyond perinatal brain injury. Microglial development is increasingly linked to neurodevelopmental disorders, epilepsy, white-matter damage and later-life neurological disease. A clearer understanding of how these cells mature could improve the interpretation of early inflammatory signals and reveal why the timing of an insult often matters as much as its severity. It may also support more rational testing of therapies intended to control harmful inflammation without blocking the beneficial immune functions needed for repair and brain development.

The study does not eliminate the complexity of translating animal research into clinical care, but it offers a practical foundation for doing so more intelligently. Its central message is that developmental biology must be treated as a measurement, not an assumption. As neonatal medicine searches for treatments that protect the vulnerable brain, comparing microglia across species may provide the biological “translation key” needed to distinguish a promising model from a misleading one. The resulting reference could become an important resource for researchers investigating how early-life injury reshapes the brain—and how those changes might be prevented.

Subject of Research: Comparative maturation of microglia in humans and mice, with implications for interpreting large-animal models of perinatal brain injury.

Article Title: Microglial maturation across human and mouse as a reference for interpreting large-animal models of perinatal brain injury

Article References: Shearer, I.K., Antonson, A., Van Steenwinckel, J. et al. “Microglial maturation across human and mouse as a reference for interpreting large-animal models of perinatal brain injury.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05355-z

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05355-z

Keywords: microglia, brain development, perinatal brain injury, neuroinflammation, human-mouse comparison, large-animal models, neonatal neuroscience, translational medicine, pediatric research

Auditory perception—the way organisms interpret and make sense of sound stimuli—is a complex process that involves integrating multifaceted sound attributes such as frequency, intensity, and temporal patterns. While mouse models have long been foundational in auditory research due to their genetic malleability and experimental accessibility, skepticism has persisted about the extent to which their perceptual frameworks parallel those of humans. This novel research offers compelling evidence that these frameworks are not only comparable but also exhibit shared underlying structures.

The study employed a sophisticated experimental design in which both human participants and mice were exposed to a wide array of tonal stimuli varying systematically across multiple auditory dimensions. Using advanced computational modeling and neural decoding techniques, the researchers were able to construct perceptual maps—conceptual frameworks representing how different sounds are internally organized within the brain’s auditory space. These maps enabled a quantifiable comparison of perceptual similarity and distance between sounds for both species, revealing a remarkable congruence in their auditory representations.

What makes these findings particularly compelling is the demonstration that these perceptual maps are predictive of behavioral outcomes during discrimination tasks. In other words, the way an individual’s brain groups different sounds predicts how well that individual can distinguish between them in learning scenarios. This link between neural representation and perceptual decision-making underlines a fundamental cognitive mechanism shared across mammalian species, offering crucial insights into the principles guiding sensory learning processes.

Beyond the fundamental science, the implications for translational research are profound. Understanding shared auditory perceptual structures facilitates the development of more accurate animal models for studying hearing impairments and neurological disorders affecting auditory processing. It also guides the design of auditory prosthetics, such as cochlear implants, by informing the algorithms that mimic natural sound perception. By aligning animal and human perceptual frameworks, therapies can be tailored with greater precision and efficacy.

A key technical achievement of the study was the use of multidimensional scaling techniques combined with machine learning algorithms to decode auditory neural responses with unprecedented granularity. The researchers collected high-resolution neural data using electrophysiological recordings in mice and non-invasive neuroimaging in humans. This dual approach allowed cross-species alignment of perceptual space, overcoming previous methodological challenges that hindered direct comparisons between human and rodent sensory processing.

Moreover, the study explored dynamic aspects of perceptual learning by measuring how auditory maps evolve through repeated training sessions. The maps exhibited plasticity reflective of learning-induced changes, emphasizing the adaptive nature of auditory perception. This plasticity was mirrored across both species, suggesting an evolutionarily conserved mechanism for tuning sensory systems based on environmental demands and experience.

One of the study’s most innovative aspects lies in its predictive modeling of discrimination performance. By mapping perceptual distances within the auditory space, the researchers could forecast individual differences in learning speed and accuracy, an advancement that holds enormous promise for personalized auditory training protocols. Such protocols could optimize rehabilitation strategies for individuals with auditory processing deficits by targeting specific perceptual aspects most relevant to their unique neural patterns.

The shared structure of auditory perceptual maps also raises intriguing questions about the evolutionary trajectory of sensory systems. The findings suggest that despite divergent evolutionary paths, fundamental auditory processing architectures remain conserved, supporting efficient sound discrimination necessary for survival and communication. This conservation across species underpins the generalizability of animal research findings to human sensory neuroscience.

Furthermore, these insights pave the way for advancing artificial sensory systems, especially in the realm of auditory artificial intelligence. By modeling computational auditory perception after natural neural maps, engineers can design more sophisticated speech recognition systems and assistive devices that better emulate human-like sound processing. The study’s integrative framework thus acts as a blueprint for creating tonal perceptual algorithms with enhanced contextual understanding.

This research also contributes importantly to theoretical debates surrounding sensory representation. By empirically demonstrating a shared, structured perceptual space, the study challenges views that sensory maps are strictly idiosyncratic or species-specific. Instead, it supports a paradigm that sensory systems leverage common organizational principles, rooted perhaps in fundamental neural coding constraints and environmental pressures shaping auditory perception.

The study’s methodology and results were meticulously detailed in a recent publication, where the authors delineated the computational techniques, behavioral paradigms, and statistical analyses that underscored their conclusions. This transparency fosters reproducibility and invites further interdisciplinary collaboration between computational neuroscientists, experimentalists, and cognitive psychologists aiming to unravel the complexities of sensory perception.

Importantly, these findings hold societal relevance beyond academic circles. Hearing loss and auditory processing disorders affect millions worldwide, often hindering communication and quality of life. Technologies and therapies inspired by a unified perceptual mapping approach could revolutionize auditory rehabilitation, offering hope for more effective interventions grounded in a thorough understanding of perceptual neuroscience.

In conclusion, this pioneering work illuminates the common auditory perceptual code shared by humans and mice, demonstrating that the brain’s representation of sound is not merely a byproduct of species-specific adaptations but a fundamental, conserved neural language. This discovery not only furthers scientific knowledge but also catalyzes innovation in medicine and technology, underscoring the power of cross-species research in unraveling the mysteries of the sensory brain.

As this field develops, future investigations are likely to explore how these perceptual maps interact with other cognitive systems such as memory and attention, and how factors such as age, experience, and pathology modulate the structure and function of auditory perception. With burgeoning advances in neurotechnologies and computational methods, the confluence of cross-species neuroscience and perceptual science promises to unlock new dimensions of understanding sensory experience.

Ultimately, the revelation that humans and mice share auditory perceptual maps that predict learning efficacies serves as a testament to nature’s optimization strategies, propelling a unified framework for deciphering sensory perception. This convergence of biology, computation, and psychology heralds a new chapter in auditory neuroscience with far-reaching implications for science and society alike.

Subject of Research: Auditory perceptual maps and discrimination learning in humans and mice

Article Title: Auditory perceptual maps in humans and mice share common structures and predict perceptual decisions in discrimination learning

Article References:
Seiler, J.PH., Cazzetta, G., Ghobadi, A. et al. Auditory perceptual maps in humans and mice share common structures and predict perceptual decisions in discrimination learning. Commun Psychol 4, 98 (2026). https://doi.org/10.1038/s44271-026-00485-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44271-026-00485-w

Synucleinopathies have long posed diagnostic challenges due to their insidious onset and often overlapping clinical features with other neurodegenerative diseases. Alpha-synuclein pathology, central to these disorders, manifests through the formation of Lewy bodies and neurites, which disrupt neural circuits critical for motor and cognitive functions. Traditionally, diagnosis has hinged upon motor symptomatology and post-mortem histopathological confirmation. However, the cognitive alterations that predate these hallmark symptoms have remained elusive, reducing the efficacy of early clinical intervention.

The study’s novelty lies in its focus on stimulus-response learning—an elemental cognitive process whereby individuals learn to associate specific stimuli with appropriate behavioral responses. Using a sophisticated animal model genetically engineered to express aberrant alpha-synuclein reflective of human synucleinopathies, the researchers meticulously assessed behavioral paradigms designed to isolate and evaluate associative learning. Results demonstrated a marked deficit in the ability to form and retain such stimulus-response associations, signaling a direct impairment attributable to synuclein pathology.

Importantly, these deficits emerged well before the development of gross motor impairments, underscoring their potential as a preclinical biomarker. The experimental paradigm employed leverages both operant conditioning frameworks and electrophysiological recordings, enabling a comprehensive characterization of the underlying neural dysfunction. Synaptic plasticity within cortico-striatal circuits—critical for stimulus-response learning—was notably disrupted, indicative of alpha-synuclein’s toxic interference with synaptic transmission.

Beyond elucidating mechanistic underpinnings, this research carries profound translational implications. The identification of stimulus-response learning impairment as an early cognitive biomarker equips clinicians and researchers with a tangible target for diagnostic tools. Cognitive testing protocols sensitive to these associative learning deficits could be refined and integrated into routine screening for individuals at risk of synucleinopathies, potentially before irreversible neurodegeneration unfolds.

From a therapeutic standpoint, the findings suggest avenues for intervention tailored to restore or enhance stimulus-response learning capabilities. Pharmacological agents modulating synaptic plasticity or novel neuromodulatory approaches such as transcranial magnetic stimulation targeting the affected neural circuits might prove efficacious in mitigating early cognitive symptoms and possibly slowing disease progression.

The research harnesses cutting-edge methodologies including in vivo calcium imaging, optogenetics, and advanced behavioral phenotyping. These techniques afford unparalleled temporal and spatial resolution in assessing neural dynamics and behavioral outcomes concurrently, painting a detailed picture of the pathological cascade initiated by alpha-synuclein accumulation.

Moreover, the study’s integrative approach bridges molecular, cellular, and systems neuroscience, enriching our understanding of how discrete synaptic pathologies translate into complex behavioral deficits. By dissecting the trajectory from molecular aberrations to functional impairment, the research delineates a pathway amenable to targeted therapeutic disruption.

This investigation further endeavors to correlate the degree of stimulus-response learning impairment with the burden and distribution of alpha-synuclein deposits, employing quantitative immunohistochemistry and magnetic resonance imaging. Such correlations reaffirm the biomarker’s specificity and prognostic value, enhancing its clinical utility.

Emerging data also hints at potential differential impacts of synucleinopathy subtypes on various domains of cognitive processing. While the current study emphasizes associative learning deficits, future research might extend these findings by exploring how distinct synuclein strains selectively disrupt neural circuits involved in memory, attention, and executive function.

Compellingly, the work ignites a broader conversation regarding the nature of cognitive biomarkers in neurodegenerative diseases. Unlike traditional markers reliant on biochemical assays or neuroimaging alone, cognitive biomarkers such as stimulus-response learning deficits provide a dynamic readout of circuit integrity and functional capacity, positioning them as invaluable complements to existing diagnostic frameworks.

Interdisciplinary collaboration underpins this advancement, with contributions spanning neurobiology, cognitive science, computational modeling, and clinical neurology. Such synergy fosters a holistic perspective essential for translating benchside discoveries into bedside benefits.

As the field progresses, the deployment of stimulus-response learning assessments in longitudinal human studies will be critical to validate and refine their predictive power. These inquiries will clarify whether early cognitive changes can indeed forecast clinical decline and serve as endpoints for therapeutic trials.

The societal and healthcare implications are profound. Early detection facilitated by this biomarker could enable timely initiation of neuroprotective therapies, lifestyle modifications, and supportive care, thereby alleviating disease burden and improving patient quality of life.

Overall, this seminal work pioneers a paradigm shift in synucleinopathy research by spotlighting an accessible cognitive domain as both a window into disease mechanisms and a measurable clinical endpoint. Its impact reverberates across neurodegenerative research, offering hope for earlier, more accurate diagnosis and innovative treatment strategies.

The study “Impairment in stimulus-response learning as a cognitive biomarker in a model of synucleinopathy” marks a significant step forward in tackling one of the most challenging facets of neurodegeneration, uniting rigorous science with translational promise to pave the way for transformative advances in patient care.

Subject of Research: Cognitive impairments, specifically stimulus-response learning deficits, as biomarkers in synucleinopathy models.

Article Title: Impairment in stimulus-response learning as a cognitive biomarker in a model of synucleinopathy.

Article References:
Princz-Lebel, O., Attaran, A., Sandoval Contreras, R. et al. Impairment in stimulus-response learning as a cognitive biomarker in a model of synucleinopathy. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-025-03795-5

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03795-5

Reinforcement learning is a fundamental brain function wherein organisms learn to associate specific behaviors with rewarding or punishing outcomes. Central to this process is the computation of reward prediction errors—the difference between expected and actual outcomes—that guide future behavior adjustment. While dopamine has long been identified as a critical neurotransmitter in this domain, the precise modulatory roles of steroid hormones such as estrogen remained elusive until now.

The multidisciplinary team, led by Golden, Martin, and Kaur, leveraged state-of-the-art neuroimaging, molecular biology techniques, and computational modeling to detail how fluctuating estrogen levels dynamically influence neuronal circuits associated with reward processing. Their rigorous approach combined in vivo recordings of neural activity with behavioral assessments in animal models to capture the essence of how estrogen shapes learning paradigms.

One of the salient discoveries from the study is that estrogen alters the magnitude and timing of reward prediction error signals in key brain regions including the ventral tegmental area (VTA) and nucleus accumbens, hubs known for their involvement in motivation and reward. This modulation was found to enhance the sensitivity of neural responses to reward contingencies, fostering more efficient learning strategies when estrogen levels are elevated.

At the molecular level, the team identified that estrogen receptors, particularly ERα and ERβ subtypes, are densely expressed in dopamine-producing neurons. Activation of these receptors appears to fine-tune dopamine release, thereby recalibrating the neural computations underlying prediction errors. Such receptor-mediated modulation highlights a sophisticated hormonal influence that goes beyond the classical view of estrogen acts solely through genomic pathways.

Another intriguing aspect of the study concerns the sex-specific nuances revealed through comparative analyses. Female subjects exhibited more pronounced shifts in reinforcement learning efficiency correlated with fluctuating estrogen concentrations across their estrous cycles. This finding proposes that cognitive processes linked to learning and reward may exhibit intrinsic variability dependent on hormonal status, potentially explaining some differential susceptibilities to neuropsychiatric conditions between sexes.

Further behavioral testing demonstrated that estrogen replacement in estrogen-depleted subjects reinstated robust reward learning capabilities, indicating potential avenues for therapeutic interventions targeting cognitive deficits. This insight is particularly relevant in conditions like depression and addiction where reinforcement learning mechanisms are often impaired and hormonal dysregulation is prevalent.

Importantly, the researchers emphasize that estrogen’s role is not unidirectional. Their data suggest a nuanced, context-dependent modulation where estrogen may either amplify or attenuate reward signaling depending on the environmental contingencies and internal states of the organism. This dynamic interplay adds a layer of complexity to existing models of neuromodulation.

Computational simulations developed by the group provided a quantitative framework illustrating how hormonal fluctuations reshape neural reward landscapes, predicting behavioral outcomes with impressive accuracy. These models integrate known biochemical pathways with neurophysiological data, serving as a powerful tool for future experimental designs and potential drug discovery efforts.

The study also raises compelling questions regarding the influence of synthetic and environmental estrogenic compounds on cognitive functions. Given the sensitivity of reinforcement learning circuits to endogenous estrogen levels, exogenous modulation through pharmaceuticals or endocrine disruptors could have unintended cognitive repercussions that warrant further investigation.

In light of these findings, the researchers advocate for a paradigm shift in neuroscience research to incorporate sex hormones as vital modulators of brain function beyond reproductive contexts. This approach is expected to refine personalized medicine strategies for neuropsychiatric disorders by factoring in hormonal status alongside genetic and environmental variables.

Moreover, this research elucidates a biological basis for the observed fluctuations in mood, motivation, and decision-making often reported across menstrual cycles in women. Understanding these underlying mechanisms presents opportunities to optimize timing and strategies for behavioral therapies and learning-based interventions.

By bridging molecular endocrinology with systems neuroscience, this study establishes a new frontier in the exploration of how intrinsic biological rhythms intersect with complex cognitive phenomena. The integration of hormonal modulation into computational frameworks and neurobiological theories marks a significant advance in the field.

Golden and colleagues’ work paves the way for future studies to explore hormone-mediated modulation in other cognitive domains such as memory, attention, and executive function. It also stimulates interdisciplinary research efforts aiming to decode the interplay between endocrine signals and brain plasticity.

In conclusion, this seminal research compels the scientific community to reevaluate the role of estrogen as a key neuromodulator in reward processing and learning. By unraveling the intricate ways in which this hormone shapes neural prediction error signals and behavioral adaptation, the study opens new vistas for understanding brain function and treating cognitive disorders with a novel, hormone-centered perspective.

Subject of Research: The neurobiological impact of estrogen on reward prediction errors and reinforcement learning mechanisms.

Article Title: Estrogen modulates reward prediction errors and reinforcement learning.

Article References:
Golden, C.E.M., Martin, A.C., Kaur, D. et al. Estrogen modulates reward prediction errors and reinforcement learning. Nat Neurosci (2025). https://doi.org/10.1038/s41593-025-02104-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41593-025-02104-z

Epileptic encephalopathies represent a group of severe brain disorders characterized by early-onset, refractory seizures and a substantial impact on cognitive development. Among the numerous molecular players involved, mutations in GABRG2—encoding the gamma-2 subunit of the GABA_A receptor—have emerged as pivotal contributors. GABA_A receptors mediate inhibitory neurotransmission in the central nervous system, thus maintaining the crucial excitatory-inhibitory balance. Dysfunctional inhibitory signaling due to GABRG2 mutations disrupts this balance, precipitating hyperexcitability and epileptogenesis.

The new mouse model described by Shen et al. incorporates a precise knock-in of a mutant GABRG2 gene variant, mirroring pathogenic human mutations. This approach enables an accurate simulation of the disease phenotype in vivo, addressing limitations of previous models which either lacked specificity or failed to exhibit spontaneous seizures. Mice carrying this mutation demonstrate spontaneous generalized seizures that resemble clinical presentations in affected patients, providing a robust platform for experimental manipulation and longitudinal studies.

Importantly, the study reveals that these genetically modified mice also exhibit significant cognitive impairments, paralleling the intellectual disabilities seen in human epileptic encephalopathy sufferers. Behavioral assays uncover deficits in learning and memory, supporting the hypothesis that GABRG2 mutations compromise not only seizure thresholds but also neural circuits governing cognition. This dual phenotype underscores the receptor’s broader role in neurodevelopment and synaptic integration beyond seizure predisposition.

Electrophysiological analyses within this model have further elucidated the disrupted inhibitory synaptic transmission attributable to GABRG2 mutations. Patch-clamp recordings from cortical neurons reveal diminished GABAergic currents, indicating a direct functional consequence of the altered gamma-2 subunit. These findings validate the hypothesis that loss of inhibitory tone leads to enhanced neuronal excitability, triggering seizures and subsequent network instability that impairs cognitive processing.

At the molecular level, the knock-in mutation appears to affect receptor assembly, trafficking, and surface expression, contributing to its functional deficits. Immunohistochemical imaging within the cerebral cortex indicates a marked reduction of functional GABA_A receptors at synaptic sites. This receptor hypofunctionality elucidates the mechanistic link between genetic mutation and clinical manifestation, emphasizing receptor biology as a targetable axis for future drug development.

The translational impact of this model is profound. By faithfully replicating the spontaneous seizure phenotype seen in human epilepsy, it sets the stage for preclinical testing of novel pharmacotherapies aimed at restoring GABAergic signaling. Moreover, it provides an invaluable tool to dissect the temporal progression of encephalopathy, discerning early pathogenetic events and windows for intervention before irreversible cognitive decline sets in.

Shen and colleagues’ work also brings renewed attention to the heterogeneity of epileptic encephalopathies, stressing the necessity for precision medicine approaches. Different mutations in GABRG2 may induce variable phenotypes, and this model facilitates comparative studies of mutant alleles under controlled genetic backgrounds. Such nuanced insights may inform patient stratification and personalized therapeutic regimens in the clinic.

In addition to its utility in epilepsy research, the novel knock-in mouse offers broader implications for neurodevelopmental disorder studies. Given the central role of GABAergic inhibition in sculpting neural circuits, disruptions as modeled here could illuminate pathways relevant to autism spectrum disorders, intellectual disabilities, and other cognitive conditions frequently comorbid with epilepsy.

Nevertheless, challenges remain in fully capturing the complexity of human pathological states in animal models. Although the knock-in approach refines genetic accuracy, interspecies differences in brain architecture and lifespan limit direct extrapolation. Ongoing refinement of behavioral paradigms and incorporation of advanced neuroimaging techniques will enhance model fidelity and facilitate deeper mechanistic understanding.

Furthermore, this study highlights the intricate interplay between genetics, neural excitability, and cognition, underscoring the brain’s vulnerability to molecular disturbances during critical developmental windows. Intervening at points where receptor dysfunction initiates epileptogenesis could radically alter disease trajectories, preventing not only seizures but also the associated cognitive morbidities.

The development of this GABRG2-specific knock-in mouse is thus a landmark achievement, merging genetic precision with phenotypic relevance. As epilepsy research advances toward targeted gene therapies, such models will be indispensable in validating efficacy and safety before clinical translation. They represent the frontline in a era where mechanistic depth meets translational promise.

In conclusion, the innovative mouse model designed by Shen et al. marks a significant step forward in decoding the enigmatic mechanisms of GABRG2-related epileptic encephalopathy. By unveiling not only seizure phenotypes but also cognitive dysfunction, it accentuates the multifaceted impact of genetic mutations on brain function. This work propels the field toward targeted therapeutics that could ultimately relieve millions affected by refractory epilepsies and associated cognitive impairments worldwide.

As research continues to unravel the complexities of inhibitory neurotransmission and epilepsy, tools such as this knock-in model will remain central to discovery efforts. They provide a powerful means to simulate human disease in the laboratory and to dissect the cascade of molecular events culminating in clinical sequelae. The future holds promise that such insights will translate into better lives for patients and their families coping with these devastating neurological disorders.

Subject of Research: GABRG2-Related Epileptic Encephalopathy and associated spontaneous seizures and cognitive impairment in a knock-in mouse model

Article Title: A knock-in mouse model for GABRG2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment

Article References:
Shen, D., Wan, J., Zhang, X. et al. A knock-in mouse model for GABRG2-related epileptic encephalopathy displays spontaneous generalized seizures and cognitive impairment. Cell Death Discov. 11, 443 (2025). https://doi.org/10.1038/s41420-025-02759-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02759-4